{
  "url": "https://allermi-site.vercel.app/allermi/allermi-vs-dymista/",
  "collection": "allermi",
  "slug": "allermi-vs-dymista",
  "frontmatter": {
    "title": "Allermi vs Dymista: Compounded vs FDA-Approved Combo",
    "description": "Compounded multi-ingredient Rx (§503A) vs FDA-approved fixed-dose azelastine + fluticasone combo.",
    "lastReviewed": "2026-04-28T00:00:00.000Z",
    "firstPublished": "2026-04-21T00:00:00.000Z",
    "author": {
      "name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://dailymed.nlm.nih.gov/",
        "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
      ]
    },
    "medicalReviewer": {
      "name": "BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology",
      "credential": "Editorial Pool",
      "sameAs": [
        "https://www.aaaai.org/",
        "https://www.acaai.org/"
      ]
    },
    "primaryKeyword": "allermi vs dymista",
    "ymylTier": "high",
    "citations": [],
    "tldr": "Dymista is an FDA-approved fixed-dose combination of azelastine + fluticasone propionate. Allermi is a §503A-compounded telehealth spray that can include up to 4 actives (azelastine + triamcinolone + ipratropium + micro-dose oxymetazoline). Dymista's finished product is FDA-approved; Allermi's compounded formula is not separately FDA-approved, but its individual ingredients are. Dymista requires a visit-based Rx; Allermi is telehealth-only.",
    "claims": [
      "c-003",
      "c-004",
      "c-009",
      "c-010",
      "c-011",
      "c-039",
      "c-040",
      "c-048",
      "c-049",
      "c-075",
      "c-078"
    ],
    "draft": false,
    "speakableSelectors": [
      ".answer-box",
      ".claim",
      "h1",
      "h2"
    ],
    "takeaways": [
      {
        "text": "Dymista = FDA-approved finished product; Allermi = compounded",
        "tier": "fda-label"
      },
      {
        "text": "Allermi includes 2 additional mechanisms (ipratropium, oxymetazoline)",
        "tier": "fda-label"
      },
      {
        "text": "Dymista has RCT evidence for its fixed combination",
        "tier": "rct",
        "detail": "Carr 2012"
      },
      {
        "text": "Allermi ~$45/mo subscription; Dymista cash $54–260 (often much lower insured)",
        "tier": "expert"
      }
    ],
    "related": [
      {
        "href": "/reviews/dymista/",
        "label": "Dymista review",
        "kind": "Product",
        "description": "FDA-approved azelastine + fluticasone combo."
      },
      {
        "href": "/reviews/allermi/",
        "label": "Allermi review",
        "kind": "Product",
        "description": "Compounded 4-active telehealth Rx."
      },
      {
        "href": "/reviews/flonase/",
        "label": "Flonase review",
        "kind": "Product",
        "description": "Dymista's steroid component alone."
      },
      {
        "href": "/reviews/astepro/",
        "label": "Astepro review",
        "kind": "Product",
        "description": "Dymista's antihistamine component alone."
      },
      {
        "href": "/allermi/allermi-vs-flonase/",
        "label": "Allermi vs Flonase",
        "kind": "Head-to-head",
        "description": "Compounded combo vs OTC steroid alone."
      },
      {
        "href": "/compare/flonase-vs-dymista/",
        "label": "Flonase vs Dymista",
        "kind": "Head-to-head",
        "description": "Steroid alone vs fixed-dose combo."
      },
      {
        "href": "/compare/flonase-vs-astepro/",
        "label": "Flonase vs Astepro",
        "kind": "Head-to-head",
        "description": "The OTC stacking equivalent of Dymista."
      },
      {
        "href": "/symptom/congestion/",
        "label": "Best nasal spray for congestion",
        "kind": "Symptom",
        "description": "Where combo therapy wins."
      },
      {
        "href": "/symptom/post-nasal-drip/",
        "label": "Best nasal spray for post-nasal drip",
        "kind": "Symptom",
        "description": "Allermi's ipratropium addresses drip that Dymista can't."
      }
    ],
    "competitor": {
      "id": "dymista",
      "name": "Dymista"
    }
  },
  "outline": [],
  "evidenceCounts": {
    "metaAnalysis": 0,
    "rct": 5,
    "guideline": 1,
    "fdaLabel": 2,
    "cohort": 0,
    "expert": 3
  },
  "claimIds": [
    "c-003",
    "c-004",
    "c-009",
    "c-010",
    "c-011",
    "c-039",
    "c-040",
    "c-048",
    "c-049",
    "c-075",
    "c-078"
  ],
  "body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\n<aside class=\"material-connection-disclosure\" role=\"note\" aria-label=\"Material connection disclosure\">**Disclosure (FTC 16 CFR Part 255):** BestAllergyNasalSprays is owned and operated by Allermi, Inc. — the company behind Allermi nasal spray. This is a [material connection](/about/ownership/) between the publisher and a reviewed product. Allermi is ranked under the same public criteria as every other product. Read the full ownership and editorial-policy disclosure [here](/about/ownership/).</aside>\n\n<Claim id=\"c-039\">Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older</Claim> <Claim id=\"c-040\">In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis</Claim> <Claim id=\"c-048\">Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)</Claim> <Claim id=\"c-011\">Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections</Claim> <Claim id=\"c-003\">Ipratropium is an anticholinergic that blocks muscarinic receptors in the nasal lining to reduce glandular secretions, helping with runny nose. As a nasal spray, it acts locally in the nasal passages</Claim> <Claim id=\"c-004\">In short-term randomized trials (up to 4 weeks), co-administering an intranasal corticosteroid with oxymetazoline has not produced rhinitis medicamentosa, and intranasal corticosteroids reverse oxymetazoline-induced tachyphylaxis once it develops; long-term safety beyond a few weeks has not been established in large randomized trials.</Claim> <Claim id=\"c-049\">In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm.</Claim> <Claim id=\"c-075\">Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone</Claim> <Claim id=\"c-078\">Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon</Claim> <Claim id=\"c-009\">Allermi is not currently prescribed during pregnancy or breastfeeding</Claim> <Claim id=\"c-010\">Allermi is currently available to eligible patients ages 13 and older across most US states</Claim>\n\n<CitationList items={[\n { id: \"1\", title: \"Carr 2012: Dymista RCT\", url: \"https://pubmed.ncbi.nlm.nih.gov/22418065/\", publisher: \"PubMed\", year: 2012 }\n]} />",
  "claims": [
    {
      "id": "c-003",
      "claim": "Ipratropium is an anticholinergic that blocks muscarinic receptors in the nasal lining to reduce glandular secretions, helping with runny nose. As a nasal spray, it acts locally in the nasal passages",
      "allermi_claim_id": "A3",
      "source_type": "StatPearls",
      "confidence": "high",
      "product_ids": [
        "allermi",
        "atrovent"
      ],
      "ymyl_tier": "medium",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.ncbi.nlm.nih.gov/books/NBK544261/"
    },
    {
      "id": "c-004",
      "claim": "In short-term randomized trials (up to 4 weeks), co-administering an intranasal corticosteroid with oxymetazoline has not produced rhinitis medicamentosa, and intranasal corticosteroids reverse oxymetazoline-induced tachyphylaxis once it develops; long-term safety beyond a few weeks has not been established in large randomized trials",
      "allermi_claim_id": "A4",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/21377716/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "qualifiers_required": [
        "short-term",
        "up to 4 weeks",
        "not been established"
      ],
      "physician_signoff": "BestAllergyNasalSprays Team"
    },
    {
      "id": "c-009",
      "claim": "Allermi is not currently prescribed during pregnancy or breastfeeding",
      "allermi_claim_id": "C2",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-010",
      "claim": "Allermi is currently available to eligible patients ages 13 and older across most US states",
      "allermi_claim_id": "C1",
      "source_type": "allermi-library",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.allermi.com/pages/eligibility"
    },
    {
      "id": "c-011",
      "claim": "Each active ingredient in Allermi is individually FDA-approved for the treatment of rhinitis. Allermi formulations are prepared by a state-licensed compounding pharmacy under the federal Food, Drug, and Cosmetic Act (section 503A); compounded drug products themselves are not FDA-approved as fixed-dose combinations and are primarily overseen by state pharmacy boards, with FDA conducting surveillance and for-cause inspections",
      "allermi_claim_id": "B3",
      "source_url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers",
      "source_type": "FDA",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard",
      "physician_signoff": "BestAllergyNasalSprays Team (legal-reviewed)"
    },
    {
      "id": "c-039",
      "claim": "Dymista is an FDA-approved fixed-dose combination nasal spray containing azelastine HCl 137 mcg and fluticasone propionate 50 mcg per spray, indicated for seasonal allergic rhinitis in patients 6 and older",
      "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c557ec4-c4cf-11df-851a-0800200c9a66",
      "source_type": "FDA-label",
      "confidence": "high",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "soft"
    },
    {
      "id": "c-040",
      "claim": "In a Phase III RCT (Carr 2012), the azelastine + fluticasone combination spray (MP29-02 / Dymista) produced significantly greater nasal-symptom relief than either agent alone or placebo in patients with moderate-to-severe seasonal allergic rhinitis",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-048",
      "claim": "Combining azelastine and fluticasone propionate (whether co-administered or as the co-formulated product Dymista / MP29-02) produces greater allergic-rhinitis symptom relief than either agent alone, demonstrated in three Phase III RCTs in moderate-to-severe seasonal allergic rhinitis (n=3,398)",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/22418065/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "dymista",
        "flonase",
        "astepro",
        "allermi"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-049",
      "claim": "In a 28-day randomized double-blind multicenter trial (Kumar 2022, n=250), a once-daily fixed-dose combination of fluticasone furoate plus oxymetazoline produced a significantly greater reduction in Total Nasal Symptom Score and a higher rate of complete nasal-congestion relief than fluticasone furoate alone, with rates of post-stoppage rebound congestion that did not differ from the steroid-only arm",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/35712651/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "allermi"
      ],
      "ymyl_tier": "hard"
    },
    {
      "id": "c-075",
      "claim": "Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone",
      "source_url": "https://pubmed.ncbi.nlm.nih.gov/10227333/",
      "source_type": "PubMed",
      "confidence": "high",
      "product_ids": [
        "atrovent",
        "allermi"
      ],
      "ymyl_tier": "medium"
    },
    {
      "id": "c-078",
      "claim": "Dymista's cash price typically ranges from about $50 to $260 per month depending on the pharmacy, and is often substantially lower with insurance coverage or a GoodRx coupon",
      "source_type": "GoodRx",
      "confidence": "medium",
      "product_ids": [
        "dymista"
      ],
      "ymyl_tier": "soft",
      "source_url": "https://www.goodrx.com/dymista"
    }
  ]
}